Biotech | April 20, 2026
FDA pushes forward on gene-editing therapies with new safety roadmap
Genome editing holds extraordinary promise for treating previously incurable genetic diseases
Genome editing holds extraordinary promise for treating previously incurable genetic diseases
The event marks a significant push into South Korea’s rapidly expanding bio-health ecosystem
The solution integrates key molecular cloning methods—including Golden Gate, Gibson assembly, and restriction/ligation—alongside primer design, Sanger sequencing analysis, and protein translation in a single application
This linear, covalently closed, double-stranded DNA offers a rapid, cell-free alternative to traditional plasmid DNA, addressing a critical bottleneck in nucleic acid therapeutics development
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
Applications include detailed scientific rationale and supporting clinical evidence
Subscribe To Our Newsletter & Stay Updated
